These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 11790589)
1. Why is the global CNS pharmaceutical market so under-penetrated? Pardridge WM Drug Discov Today; 2002 Jan; 7(1):5-7. PubMed ID: 11790589 [No Abstract] [Full Text] [Related]
2. Digital phenotyping approaches and mobile devices enhance CNS biopharmaceutical research and development. Smith DG Neuropsychopharmacology; 2018 Dec; 43(13):2504-2505. PubMed ID: 30267015 [No Abstract] [Full Text] [Related]
4. Is pharma running out of brainy ideas? Miller G Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165 [No Abstract] [Full Text] [Related]
5. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics. Yokley BH; Hartman M; Slusher BS ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461 [TBL] [Abstract][Full Text] [Related]
6. By the numbers. Suppliers/purchasing. Mod Healthc; 2007 Dec; Suppl():70, 72, 74 passim. PubMed ID: 18220137 [No Abstract] [Full Text] [Related]
7. Drugs: budget busters or cost cutters in future health care? Egger E Health Care Strateg Manage; 1999 Mar; 17(3):1, 22-3. PubMed ID: 10351640 [No Abstract] [Full Text] [Related]
9. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases. Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722 [TBL] [Abstract][Full Text] [Related]
10. The blood-brain barrier: clinical implications for drug delivery to the brain. De Boer AG; Breimer DD J R Coll Physicians Lond; 1994; 28(6):502-6. PubMed ID: 7884704 [TBL] [Abstract][Full Text] [Related]
11. Clinical Trials in CNS--SMi's Seventh Annual Conference. 25-26 November 2008, London, UK. Sherwood D IDrugs; 2009 Feb; 12(2):84-6. PubMed ID: 19204879 [No Abstract] [Full Text] [Related]
12. Drugmakers plow more resources into autism. Sheridan C Nat Biotechnol; 2013 May; 31(5):367-9. PubMed ID: 23657371 [No Abstract] [Full Text] [Related]
13. Upcoming market catalysts in Q4 2009. Jatkoe L Nat Rev Drug Discov; 2009 Oct; 8(10):763. PubMed ID: 19794437 [No Abstract] [Full Text] [Related]
14. By the numbers. Top 20 pharmaceutical companies. Ranked by U.S. sales, April 2003 through March 2004. Moon S Mod Healthc; 2004 Aug; 34(33):40. PubMed ID: 15356990 [No Abstract] [Full Text] [Related]
16. Market watch: industry perspectives on personalized medicine. Zuckerman R; Milne CP Nat Rev Drug Discov; 2012 Mar; 11(3):178. PubMed ID: 22378258 [No Abstract] [Full Text] [Related]
17. Proceedings of the 2013 CINP summit: innovative partnerships to accelerate CNS drug discovery for improved patient care. Phillips AG; Hongaard-Andersen P; Moscicki RA; Sahakian B; Quirion R; Krishnan KR; Race T Int J Neuropsychopharmacol; 2014 Dec; 18(3):. PubMed ID: 25542690 [TBL] [Abstract][Full Text] [Related]
18. Central nervous system drug development, basic, and clinical research: thinking outside the box. Klein DF; Glick ID; Shader RI J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701 [No Abstract] [Full Text] [Related]
19. Trends in the market for antihypertensive drugs. Ali MA; Rizvi S; Syed BA Nat Rev Drug Discov; 2017 May; 16(5):309-310. PubMed ID: 28280260 [No Abstract] [Full Text] [Related]
20. Estimate of the global market for rifampicin-containing fixed-dose combination tablets. Norval PY; Blomberg B; Kitler ME; Dye C; Spinaci S Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S292-300; discussion S317-21. PubMed ID: 10593708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]